The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 14, 2017

Filed:

Feb. 22, 2013
Applicant:

Alteogen Inc., Daejeon, KR;

Inventors:

Soon Jae Park, Daejeon, KR;

Hye-Shin Chung, Daejeon, KR;

Seonhun Kwon, Seoul, KR;

Sunbae Lee, Daejeon, KR;

Sun-ah Yoo, Daejeon, KR;

Yong Mo Kim, Jeoneup-si, KR;

Assignee:

ALTEOGEN INC., Daejeon, KR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); A61K 47/65 (2017.01); C07K 16/00 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01); A61K 31/704 (2006.01); A61K 38/07 (2006.01); A61K 38/08 (2006.01); A61K 47/48 (2006.01);
U.S. Cl.
CPC ...
A61K 47/48584 (2013.01); A61K 31/704 (2013.01); A61K 38/07 (2013.01); A61K 47/65 (2017.08); A61K 47/6803 (2017.08); A61K 47/6809 (2017.08); A61K 47/6817 (2017.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61K 47/6855 (2017.08); A61K 47/6871 (2017.08); C07K 16/00 (2013.01); C07K 16/30 (2013.01); C07K 16/3015 (2013.01); C07K 16/32 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01);
Abstract

The present invention relates to an antibody in which a motif composed of an amino acid or peptide sequence including one or more cysteine residues is bound to the terminus of a parent antibody, particularly the terminus of the heavy chain of the parent antibody. Also, the present invention relates to a modified antibody-drug conjugate (mADC) comprising a drug bound to the antibody, and a method for producing the antibody or the modified antibody-drug conjugate. The modified antibody-drug conjugate according to the invention can accurately deliver the drug to a target cell due its high specificity to antigen, and thus can increase the therapeutic effect of the drug. Also, it can increase the usability of drugs, particularly anticancer drugs, the use of which is restricted due to their toxicity, despite their high efficacy. Moreover, the invention relates to a composition for treatment of diseases, particularly cancers, which comprise the modified antibody-drug conjugate.


Find Patent Forward Citations

Loading…